Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €73.20 EUR
Change Today -0.01 / -0.01%
Volume 20.0K
As of 11:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Open
€73.33
Previous Close
€73.21
Day High
€73.33
Day Low
€71.76
52 Week High
07/20/15 - €83.48
52 Week Low
09/1/14 - €21.27
Market Cap
1.7B
Average Volume 10 Days
43.0K
EPS TTM
€-1.49
Shares Outstanding
23.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment peanut allergies in children, adolescents, and adults; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis (EoE); and Viaskin Egg, a development program for the treatment of hen’s egg allergy. The company also develops other earlier stage product development programs, which comprise house dust mites allergy, EoE, pertusiss boost vaccine, and birch pollen allergy. DBV Technologies S.A. was founded in 2002 and is based in Bagneux, France.

63 Employees
Last Reported Date: 07/27/15
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €427.7K
Compensation as of Fiscal Year 2014.

dbv technologies sa (DBV) Key Developments

DBV Technologies Announces Earnings Results for the First Half Year of 2015

DBV Technologies announced earnings results for the first half year of 2015. For the period, the company reported total revenues were EUR 3.17 million against EUR 2.66 million a year ago. These revenues were primarily generated from government research tax credits and, to a lesser extent, from sales of Diallertest and from research subsidies. Operating loss was EUR 14.92 million against EUR 12.08 million a year ago. Net loss was EUR 14.48 million against EUR 11.77 million a year ago. Loss per share was EUR 0.74 against EUR 0.77 a year ago. Net cash flow used in operating activities was EUR 12.44 million against EUR 10.47 million a year ago.

U.S. Food and Drug Administration Accepts New Drug Application forPhase IIA Clinical Trial for eosinophilic esophagitis of DBV Technologies

DBV Technologies announced that the U.S. Food and Drug Administration (FDA) has accepted an investigator-sponsored investigational new drug (IND) application for a Phase IIA clinical trial for the potential treatment of milk-induced eosinophilic esophagitis (EoE) in children using the Company's Viaskin Milk. This IND acceptance enables Dr. Jonathan Spergel at The Children's Hospital of Philadelphia to initiate SMILEE (Study Efficacy and Safety of the Viaskin Milk in milk-induced Eosinophilic Esophagitis), a clinical trial designed to assess the efficacy and safety of Viaskin Milk in children four to 17 years of age suffering from milk-induced EoE. The SMILEE trial is expected to begin in the second half of 2015. SMILEE is expected to be a double-blind, placebo-controlled, randomized 3:1 trial designed to evaluate the safety and efficacy of Viaskin Milk 500 g for treating milk-induced EoE in children. Subjects with a documented medical history of EoE after ingestion of milk who currently adhere to a strict milk-free diet will be considered for participation in the trial. Approximately 20 subjects, 15 in the treatment group and five in the placebo group, will be randomized and treated for nine months while remaining on a milk-free diet. The treatment group will then continue the trial during a milk reintroduction period (1 week to 2 months), for a total of up to 11 months of treatment. The primary efficacy endpoint will be evaluated as the maximum esophageal eosinophil count in the treatment group compared to placebo at the end of treatment. Secondary efficacy endpoints will include the change in symptoms score at the end of treatment compared to baseline and mean esophageal eosinophil count at the end of treatment.

DBV Technologies Announces New Drug (IND) Application for A Phase IIA Clinical Trial

DBV Technologies announced that the U.S. Food and Drug Administration has accepted an investigator-sponsored investigational new drug (IND) application for a Phase IIA clinical trial for the potential treatment of milk-induced eosinophilic esophagitis (EoE) in children using the Company's Viaskin Milk. This IND acceptance enables Dr. Jonathan Spergel at The Children's Hospital of Philadelphia to initiate SMILEE (Study Efficacy and Safety of the Viaskin Milk in milk-induced Eosinophilic Esophagitis), a clinical trial designed to assess the efficacy and safety of Viaskin Milk in children four to 17 years of age suffering from milk-induced EoE. The SMILEE trial is expected to begin in the second half of 2015. SMILEE is expected to be a double-blind, placebo-controlled, randomized 3:1 trial designed to evaluate the safety and efficacy of Viaskin Milk 500 microgramme for treating milk-induced EoE in children.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €73.20 EUR -0.01

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aimmune Therapeutics Inc $21.11 USD -0.24
Immune Design Corp $16.61 USD +0.17
View Industry Companies
 

Industry Analysis

DBV

Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 276.6x
Price/Book 13.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 311.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit www.dbv-technologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.